These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11897645)

  • 1. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity.
    Rossman MD; Stubbs J; Lee CW; Argyris E; Magira E; Monos D
    Am J Respir Crit Care Med; 2002 Mar; 165(6):788-94. PubMed ID: 11897645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.
    Maier LA; McGrath DS; Sato H; Lympany P; Welsh K; Du Bois R; Silveira L; Fontenot AP; Sawyer RT; Wilcox E; Newman LS
    J Immunol; 2003 Dec; 171(12):6910-8. PubMed ID: 14662898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69.
    Amicosante M; Berretta F; Rossman M; Butler RH; Rogliani P; van den Berg-Loonen E; Saltini C
    Respir Res; 2005 Aug; 6(1):94. PubMed ID: 16098233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of sensitivity to beryllium in mice.
    Tarantino-Hutchison LM; Sorrentino C; Nadas A; Zhu Y; Rubin EM; Tinkle SS; Weston A; Gordon T
    J Immunotoxicol; 2009 Jun; 6(2):130-5. PubMed ID: 19589099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenetic factors in beryllium sensitization and chronic beryllium disease.
    Weston A; Snyder J; McCanlies EC; Schuler CR; Andrew ME; Kreiss K; Demchuk E
    Mutat Res; 2005 Dec; 592(1-2):68-78. PubMed ID: 16054169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.
    Silveira LJ; McCanlies EC; Fingerlin TE; Van Dyke MV; Mroz MM; Strand M; Fontenot AP; Bowerman N; Dabelea DM; Schuler CR; Weston A; Maier LA
    J Immunol; 2012 Oct; 189(8):4014-23. PubMed ID: 22972925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles.
    Wang Z; White PS; Petrovic M; Tatum OL; Newman LS; Maier LA; Marrone BL
    J Immunol; 1999 Aug; 163(3):1647-53. PubMed ID: 10415070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DPB1 E69 genotype and exposure in beryllium sensitisation and disease.
    Crooks J; Mroz MM; VanDyke M; McGrath A; Schuler C; McCanlies EC; Virji MA; Rosenman KD; Rossman M; Rice C; Monos D; Fingerlin TE; Maier LA
    Occup Environ Med; 2022 Feb; 79(2):120-126. PubMed ID: 34535537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.
    Van Dyke MV; Martyny JW; Mroz MM; Silveira LJ; Strand M; Fingerlin TE; Sato H; Newman LS; Maier LA
    Am J Respir Crit Care Med; 2011 Jun; 183(12):1680-8. PubMed ID: 21471109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic beryllium disease: a hypersensitivity disorder.
    Rossman MD
    Appl Occup Environ Hyg; 2001 May; 16(5):615-8. PubMed ID: 11370939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization.
    McCanlies EC; Ensey JS; Schuler CR; Kreiss K; Weston A
    Am J Ind Med; 2004 Aug; 46(2):95-103. PubMed ID: 15273960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease.
    Kreiss K; Fechter-Leggett ED; McCanlies EC; Schuler CR; Weston A
    J Occup Environ Med; 2016 Sep; 58(9):855-60. PubMed ID: 27414009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity.
    Rosenman KD; Rossman M; Hertzberg V; Reilly MJ; Rice C; Kanterakis E; Monos D
    Occup Environ Med; 2011 Jul; 68(7):487-93. PubMed ID: 21186201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals.
    Sato H; Spagnolo P; Silveira L; Welsh KI; du Bois RM; Newman LS; Maier LA
    Tissue Antigens; 2007 Dec; 70(6):480-6. PubMed ID: 17927685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease.
    Maier LA; Sawyer RT; Bauer RA; Kittle LA; Lympany P; McGrath D; Dubois R; Daniloff E; Rose CS; Newman LS
    Am J Respir Crit Care Med; 2001 Oct; 164(7):1192-9. PubMed ID: 11673208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
    Richeldi L; Sorrentino R; Saltini C
    Science; 1993 Oct; 262(5131):242-4. PubMed ID: 8105536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
    Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
    Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease.
    Snyder JA; Demchuk E; McCanlies EC; Schuler CR; Kreiss K; Andrew ME; Frye BL; Ensey JS; Stanton ML; Weston A
    J R Soc Interface; 2008 Jul; 5(24):749-58. PubMed ID: 17956852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in understanding the biomolecular basis of chronic beryllium disease: a review.
    McCleskey TM; Buchner V; Field RW; Scott BL
    Rev Environ Health; 2009; 24(2):75-115. PubMed ID: 19658317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.
    Bill JR; Mack DG; Falta MT; Maier LA; Sullivan AK; Joslin FG; Martin AK; Freed BM; Kotzin BL; Fontenot AP
    J Immunol; 2005 Nov; 175(10):7029-37. PubMed ID: 16272364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.